EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-NUBF-07(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Percutaneous core injection of autologous Bone Marrow Aspirate Concentrate (BMAC) is an established point-of-care orthobiologic procedure for aseptic, mechanically stable non-unions. The use of culture-expanded, ex vivo manipulated, or allogeneic mesenchymal stem cells is strictly investigational and experimental under Indian Council of Medical Research (ICMR) and National Medical Commission (NMC) guidelines.
Pathophysiology & Disease Context:
A non-union occurs when a fractured bone fails to heal progressively (typically $>6\text{ to }9$ months post-injury without bridging signs for 3 consecutive months), presenting as persistent local pain, abnormal mobility, and mechanical instability.
Biological Rationale & Paracrine Action:
Delivers concentrated autologous osteoprogenitor cells (colony-forming unit-fibroblasts [CFU-Fs]) and essential osteoinductive cytokines (BMP-2, TGF-$\beta$, VEGF, FGF) directly into the non-union gap to reinitiate stalled endochondral and intramembranous ossification without open surgical trauma.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Individuals with chronic, non-healing long-bone fractures (femur, tibia, humerus, radius, ulna, or clavicle) categorized as hypertrophic or oligotrophic non-union with existing stable mechanical fixation (plates, intramedullary nails, or external fixators).
Mandatory Pre-Procedure Diagnostics:
High-resolution CT scan (< 1 month old) assessing cross-sectional cortical continuity and gap size ($<1\text{ cm}$), serial orthogonal radiographs, inflammatory markers (ESR, hs-CRP) to rule out occult infection, serum 25(OH) Vitamin D, calcium, and intact PTH.
Strict Safety Exclusion Parameters:
Active septic non-union or chronic osteomyelitis; severe hardware failure or mechanical instability (loose screws, broken nails) requiring surgical revision; large segmental bone defects ($>1\text{ to }2\text{ cm}$ requiring structural bone transport/Masquelet grafting); or active local malignant lesions.
Triage Protocol & Multi-Specialty Clearance:
Dual-surgeon review by a fellowship-trained orthopedic trauma surgeon and limb reconstruction specialist before issuing international travel clearance.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Bridging Callus Formation: Progressive mineralization and continuous bridging across at least 3 of 4 cortices on follow-up radiographs and CT.
- Fracture Site Pain Relief: Rapid reduction in localized weight-bearing tenderness and motion-induced discomfort (VAS scores).
- Early Functional Weight-Bearing: Safe progression to full unassisted weight-bearing and ambulatory independence.
- Avoidance of Major Open Surgery: Stimulating natural biological repair while avoiding the morbidity of open revision surgery or extensive iliac crest structural bone harvesting.
Documented Procedural Risks & Limits:
- Self-limiting donor-site (iliac crest) tenderness, mild bruising, or localized swelling at the fracture injection track lasting 48–72 hours.
- Rare risks: localized hematoma or failure to achieve bony bridging if mechanical fixation is micro-unstable.
- No Guaranteed Union: Biologic cellular therapy cannot overcome persistent mechanical instability, active infection, or large segmental gaps; tobacco use significantly compromises cellular engraftment and osteogenesis.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited Campus
Procedures performed exclusively in tertiary trauma and orthopedic centers accredited by NABH and JCI.
% C-Arm Fluoroscopic Guidance
Every cellular depot is verified under high-resolution fluoroscopy to confirm accurate intralesional delivery into the non-union gap.
Experienced Trauma Faculty
Supervised directly by fellowship-trained trauma surgeons and limb reconstruction specialists experienced in non-union salvaging techniques.
Ethical Standards
Full alignment with National Medical Commission (NMC) standards; patients with mechanical instability or infected bone are directed toward hardware revision and debridement rather than non-indicated biologics.
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Pre-Arrival Video Consultation
Remote telemedicine conference with senior trauma surgeons to evaluate CT cuts, assess fixation stability, and determine candidate viability.
Government Medical Visa
Expedited documentation assistance for official Government of India Medical Visa (MED) and Medical Attendant (MED-X) approvals.
Dedicated Case Liaison
Single multilingual point of contact coordinating airport reception, priority clinical appointments, and medical documentation.
Structured Remote Follow-Up
Virtual reviews at Months 1, 2, 3, and 6, coordinating serial radiographs and callus measurements directly with your local orthopedic surgeon.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Sanitized Transfers
Private, air-conditioned vehicle pick-up and drop-off accommodating wheelchairs, crutches, and limb splints to ensure smooth, low-jarring transit.
Accessible Partner Accommodations
Partner 4-star and 5-star serviced apartments located within 10 minutes of the center, featuring step-free access, elevators, walk-in showers with grab rails, and firm supportive beds.
Bone-Supportive Amenities
High-protein, bone-mineralizing nutritional meal options supervised by clinical dietitians, local SIM registration, and 24/7 on-call nursing access.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: 2 to 3 days day-care / short-stay orthopedic pathway.):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Non-Union Bone Fractures
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Landmark Prospective Trial on Percutaneous Autologous Bone Marrow Grafting in Atrophic Non-Unions
Hernigou, P., Poignard, A., Beaujean, F., & Rouard, H. (2005). Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. The Journal of Bone and Joint Surgery (American Volume), 87(7), 1430–1437.
Randomized Controlled Trial: BMAC Injection vs. Open Autologous Iliac Crest Bone Grafting
Jäger, M., Hernigou, P., Fischer, C., Bühren, V., Kasten, P., & Krauspe, R. (2011). Bone Marrow Concentrate (BMC) for Bone Healing: A Multicenter Randomized Controlled Trial on Long Bone Non-Unions. Injury, 42(Suppl 2), S40–S46. / Liebergall, M., et al. (2013). Stem cell therapy for non-unions: A randomized controlled clinical trial. Journal of Orthopaedic Trauma, 27(10), 570–576.
Prospective Multicenter Study on Percutaneous BMAC for Long-Bone Delayed and Non-Union
Desai, M. J., Marimuthu, K., Kalia, R. B., & Aggarwal, S. (2015). Percutaneous bone marrow aspirate concentrate injection for the management of delayed union and nonunion of long bones: A prospective evaluation. Indian Journal of Orthopaedics, 49(5), 509–515.
Systematic Review & Meta-Analysis of Percutaneous Cell Therapy for Fracture Non-Unions
Zhong, H. Y., Cheng, L. X., Ding, X. B., & Hu, J. B. (2021). Efficacy and Safety of Autologous Bone Marrow Aspirate Concentrate (BMAC) in the Treatment of Nonunion: A Systematic Review and Meta-Analysis. Frontiers in Surgery, 8, 725458.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), autologous point-of-care orthobiologics (such as BMAC used during percutaneous grafting) must adhere to minimal manipulation standards. The administration of ex vivo cultured, expanded, or allogeneic mesenchymal stem cells for non-union fractures is categorized as strictly investigational and experimental. Orthobiologic injections are intended for mechanically stable, aseptic non-unions and cannot substitute for surgical revision or fixation when hardware has failed or large structural gaps exist. Patients must adhere strictly to prescribed weight-bearing restrictions during the consolidation phase.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.